Both drugs have randomized trial evidence for neuropathic pain, and in a 2025 systematic review and meta-analysis in Frontiers in Pain Research, pregabalin produced greater improvement in pain scores than gabapentin from four weeks onward, through 12 to 14 weeks of follow-up [1]. The same review found no significant difference between the two in dizziness or somnolence, though gabapentin showed a higher incidence of nausea and vomiting [1]. What the evidence does not support is treating either drug as an answer to the injury that is generating the pain signal.
Neuropathic pain is common enough that the question comes up constantly. Prevalence in the general population is estimated to range from 3.2% to 10.3% [1]. People across the St. Louis region, Missouri and Illinois ask us the same thing: are these medicines worth taking, and what else should be happening at the same time?
Key points
- Gabapentin and pregabalin are gabapentinoids. They act on pain signaling; they do not correct the metabolic, nutritional, autoimmune, toxic or structural driver behind the injury.
- Comparative trial evidence favors pregabalin on pain intensity and on patient-reported quality of life over 12 to 14 weeks [1].
- Dizziness and somnolence are the adverse events most often reported for both, and the most common reasons people stop [2].
- Neuropathy is a category, not a diagnosis. The driver decides what else belongs in the plan.
- Start by identifying which driver is doing the most damage, then decide what role, if any, a gabapentinoid should play.
What the comparative evidence actually shows
Pain intensity
The 2025 meta-analysis pooled randomized trials comparing the two drugs directly in neuropathic pain. Pregabalin showed significantly greater pain improvement than gabapentin at four weeks and onward, with most primary comparisons falling at 12 to 14 weeks of follow-up [1].
A better average in pooled trial data is not a promise about your result. It tells you which drug is more likely to help, not whether the mechanism causing your symptoms is being addressed.
Quality of life and function
The same review reported significantly greater improvement in general health-related quality-of-life scores for pregabalin compared with gabapentin [1]. When burning feet are interfering with sleep, a change in function can matter more than a change in a single pain score.
We also look at what else a patient is taking for pain, because the goal is to reduce the overall burden rather than add another prescription to it.
Side effects that decide whether people stay on treatment
Tolerability drives adherence. In neuropathic pain trials, dizziness and somnolence were the most commonly reported adverse events for both pregabalin and gabapentin compared with placebo, and were the most common reasons for stopping either medicine [2].
Why this matters more in older adults
Dizziness and sleepiness raise fall risk and blunt daytime activity. Before starting or increasing a gabapentinoid, the review should cover other sedating medications, alcohol intake and the conditions that amplify those effects.
Stopping matters too. New Zealand’s Centre for Adverse Reactions Monitoring had received seven reports of withdrawal syndrome for pregabalin and seven for gabapentin as of June 2020 [2]. Changes should be planned with the prescriber, not made abruptly.
Why a medication answer is not a complete answer
Neuropathy is a category, not a diagnosis
Burning, numbness and electric sensations describe how damaged nerves misfire. They do not tell you what is damaging them. Metabolic injury, nutritional deficiency, autoimmune activity, toxic exposure and structural compression all produce overlapping symptoms.
That is why we treat the terrain around the nerve rather than only the signal coming off it. A gabapentinoid can quiet the alarm while the emergency continues.
Where testing fits
Electrodiagnostic testing (EMG/NCS) is performed on site and helps characterize large-fiber involvement. When the pattern suggests small fiber neuropathy, standard nerve conduction studies can be normal, so the evaluation has to extend beyond them.
Balance complaints are evaluated separately with videonystagmography (VNG), which is a diagnostic test of inner-ear balance function. It is not a treatment.
What sits alongside gabapentinoids in our plans
Qutenza (capsaicin 8% patch)
Qutenza is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician, is never dispensed for home use, and is repeated no more often than every three months. Use for any other neuropathy driver is off-label and we describe it that way.
In-clinic light and laser therapies
We also offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared. These are used as part of a driver-based plan rather than as substitutes for identifying what is injuring the nerve.
Orthobiologic injections (PRP and BMAC) are offered in selected situations. The framework behind all of it is described in the Regenerve Protocol for peripheral neuropathy.
Frequently asked questions
Does pregabalin work better than gabapentin for neuropathic pain?
In a 2025 systematic review and meta-analysis of randomized trials, pregabalin produced greater improvement in pain scores than gabapentin from four weeks onward through 12 to 14 weeks of follow-up. That is an average across trial populations, not a prediction for one person, which is why we map the driver first. See the hidden drivers of peripheral neuropathy.
What side effects do people notice first?
Dizziness and somnolence were the most commonly reported adverse events for both pregabalin and gabapentin compared with placebo in neuropathic pain trials, and were also the most common reasons people stopped treatment. In older adults those effects can affect balance and daytime function, so they are worth reviewing at every visit. See small fiber neuropathy symptoms and testing.
Is there a non-oral option for burning feet?
Qutenza (capsaicin 8% patch) is FDA-approved in adults for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. It is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months; use for any other neuropathy driver is off-label. See Qutenza (capsaicin 8% patch).
Should I have nerve testing before starting a gabapentinoid?
Electrodiagnostic testing (EMG/NCS) helps establish whether the pattern fits a large-fiber peripheral neuropathy and where the problem sits. It is less informative when the symptoms point to small fiber involvement, so the testing plan should follow the symptom pattern. We perform EMG/NCS on site; see our services and on-site testing.
Can I stop gabapentin or pregabalin on my own?
No. Withdrawal reactions have been reported to national pharmacovigilance monitoring for both medicines, so any change should be planned with the prescriber rather than made abruptly. Symptom control and driver work usually need to be adjusted together. See peripheral neuropathy treatments for the feet.
Next step
Five questions identify which driver is doing the most damage right now. Start there, then decide what role gabapentin or pregabalin should play in your plan.
Sources
- Mayoral V, et al. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety. Frontiers in Pain Research (Lausanne). 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11747324/
- Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Spotlight on gabapentin and pregabalin for neuropathic pain. Prescriber Update 42(1):3, 4 March 2021. https://www.medsafe.govt.nz/profs/PUArticles/March2021/Spotlight-on-gabapentin-and-pregabalin-for-neuropathic-pain.html